The EPS projection of Dolby Laboratories (NYSE:DLB) for quarter ended 2016-09-30 is $0.29. A week before, the EPS forecast was $0.29 against target of $0.29, a month earlier. This estimate stood at $0.29 60 days earlier versus forecast of $0.29 90 days earlier, confirming a deviation of 0%.
Dolby Laboratories (NYSE:DLB) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 4.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 0, 0 and 0, respectively.
The downgrade of EPS estimates for Dolby Laboratories (NYSE:DLB) in the preceding 120, 60, 30 and 90 days were 4, 4, 0 and 4, in that order.
As per the latest update, for the quarter closed 2, the EPS estimate of Dolby Laboratories (NYSE:DLB) was $0.29. This projection was computed after accounting 5 calls. As reported on 2016-04-27 the EPS was $0.66. The change was $0.2, demonstrating a percentage deviation of 43.48%. The projections confirmed a standard deviation of 0.01.
Quarterly Sales Estimates
For the fiscal 2017, the yearly sales target for Dolby Laboratories (NYSE:DLB) stands at $259.043 and the median estimate at $257.727. Almost 4 analysts announced their estimates.
The highest estimate is $263.93 while the lowest target is $256.79 showing standard deviation of 3.335%.
As many as 4 analysts released sales estimates reised in upside while 4 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 4 revised sales number projection on upside while 4 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 4 hiked sales estimations and 4 reduced sales forecast. Dolby Laboratories (NYSE:DLB) stated that the change in forecast was -4.971%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...